Lysophosphatidic acid and its receptors LPA(1) and LPA(3) mediate paclitaxel-induced neuropathic pain in mice

BACKGROUND: Paclitaxel, which is widely used for the treatment of solid tumors, causes neuropathic pain via poorly understood mechanisms. Previously, we have demonstrated that lysophosphatidic acid (LPA) and its receptors (LPA(1) and LPA(3)) are required for the initiation of peripheral nerve injury...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Hitoshi, Nagai, Jun, Ueda, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246549/
https://www.ncbi.nlm.nih.gov/pubmed/25411045
http://dx.doi.org/10.1186/1744-8069-10-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246549/
https://www.ncbi.nlm.nih.gov/pubmed/25411045
http://dx.doi.org/10.1186/1744-8069-10-71

Ejemplares similares